Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone

BACKGROUND: Combination therapy with an inhaled corticosteroid (ICS) and long-acting β(2) agonist (LABA) is recommended for patients with asthma symptomatic on ICS alone. However, there is ongoing debate regarding the risk-benefit ratio of using LABA in asthma. OBJECTIVE: To evaluate the effect of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bateman, Eric D, O'Byrne, Paul M, Busse, William W, Lötvall, Jan, Bleecker, Eugene R, Andersen, Leslie, Jacques, Loretta, Frith, Lucy, Lim, Jessica, Woodcock, Ashley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Asthma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963539/
https://www.ncbi.nlm.nih.gov/pubmed/24253831
http://dx.doi.org/10.1136/thoraxjnl-2013-203600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963539/
https://www.ncbi.nlm.nih.gov/pubmed/24253831
http://dx.doi.org/10.1136/thoraxjnl-2013-203600

Ejemplares similares